Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma
- First Online:
- Cite this article as:
- Tonziello, G., Pisaturo, M., Sica, A. et al. Infection (2013) 41: 225. doi:10.1007/s15010-012-0305-y
A female patient with non-Hodgkin lymphoma who tested positive for surface antigen of the hepatitis B virus and negative for hepatitis B core antibody experienced a reactivation of occult HBV infection 20 months after rituximab discontinuation despite lamivudine prophylaxis covering the 4 months of rituximab administration and the subsequent 12 months.